Omada Health Delivers on 2025 Growth and Profitability, Validating Key Catalysts but Risks Linger

What happened

Omada Health reported fourth-quarter revenue growth of 58% and full-year growth of 53%, alongside 55% member growth for 2025, meeting preliminary estimates and sustaining its high-growth narrative. The company achieved positive net income in Q4 and positive adjusted EBITDA for the full year, significantly narrowing its net loss and demonstrating operational leverage. These audited results confirm the $256M-$258M revenue range, addressing a critical verification point from the DeepValue report and meeting the condition for increasing the investment call. However, the GLP-1 prescribing launch—a key catalyst—remains pending for 1H26, and partner concentration with Cigna continues to pose a material risk. Internal control weaknesses, previously flagged as ineffective, require ongoing remediation to bolster investor confidence in financial reporting.

Implication

Positive adjusted EBITDA and aligned audited numbers reduce near-term profitability concerns, supporting a potential re-rating if management maintains this momentum. Credibility improves with verified growth, yet the material weakness in internal controls demands swift remediation to avoid future scrutiny. Sustained member growth above 50% justifies the premium multiple, but reliance on Cigna for over $100M in revenue highlights vulnerability to channel slowdowns. The upcoming GLP-1 prescribing launch is now the focal point; success could boost ARPU and margins, while failure would undermine the growth narrative. Investors should assess 2026 guidance for signs of sustained >30% revenue growth and stable profitability, balancing optimism with critical oversight of execution risks.

Thesis delta

The audited results meeting preliminary estimates and achieving positive adjusted EBITDA shift the thesis toward the base or bull scenario, validating operational leverage and reducing downside risk. This increases confidence in near-term execution, but the investment call remains contingent on successful GLP-1 launch in 1H26 and sustained growth without partner disruption.